143 related articles for article (PubMed ID: 19491659)
21. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Nagy A; Schally AV
Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
[TBL] [Abstract][Full Text] [Related]
22. [New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin].
Schally AV
An R Acad Nac Med (Madr); 2004; 121(3):493-500. PubMed ID: 15751842
[TBL] [Abstract][Full Text] [Related]
23. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
Krebs LJ; Wang X; Pudavar HE; Bergey EJ; Schally AV; Nagy A; Prasad PN; Liebow C
Cancer Res; 2000 Aug; 60(15):4194-9. PubMed ID: 10945629
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy targeted to cancers through tumoral hormone receptors.
Schally AV; Nagy A
Trends Endocrinol Metab; 2004 Sep; 15(7):300-10. PubMed ID: 15350601
[TBL] [Abstract][Full Text] [Related]
25. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts.
Tejeda M; Gaal D; Barna K; Csuka O; Kéri G
Anticancer Res; 2003; 23(5A):4061-6. PubMed ID: 14666719
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
Burke PJ; Koch TH
J Med Chem; 2004 Feb; 47(5):1193-206. PubMed ID: 14971899
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin-polyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics.
Chun C; Lee SM; Kim CW; Hong KY; Kim SY; Yang HK; Song SC
Biomaterials; 2009 Sep; 30(27):4752-62. PubMed ID: 19520429
[TBL] [Abstract][Full Text] [Related]
28. Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
Keller G; Schally AV; Nagy A; Baker B; Halmos G; Engel JB
Int J Oncol; 2006 Jun; 28(6):1507-13. PubMed ID: 16685451
[TBL] [Abstract][Full Text] [Related]
29. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
Emons G; Sindermann H; Engel J; Schally AV; Gründker C
Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
[TBL] [Abstract][Full Text] [Related]
30. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
Keller G; Engel JB; Schally AV; Nagy A; Hammann B; Halmos G
Int J Cancer; 2005 May; 114(5):831-5. PubMed ID: 15609311
[TBL] [Abstract][Full Text] [Related]
31. Targeting breast and prostate cancers through their hormone receptors.
Leuschner C; Hansel W
Biol Reprod; 2005 Nov; 73(5):860-5. PubMed ID: 16033998
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238.
Kahán Z; Nagy A; Schally AV; Hebert F; Sun B; Groot K; Halmos G
Int J Cancer; 1999 Aug; 82(4):592-8. PubMed ID: 10404076
[TBL] [Abstract][Full Text] [Related]
33. Urease-induced alkalinization of extracellular pH and its antitumor activity in human breast and lung cancers.
Wong WY; DeLuca CI; Tian B; Wilson I; Molund S; Warriar N; Govindan MV; Segal D; Chao H
J Exp Ther Oncol; 2005; 5(2):93-9. PubMed ID: 16475272
[TBL] [Abstract][Full Text] [Related]
34. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models.
Tejeda M; Gaál D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri G
Anticancer Res; 2006; 26(4B):3011-5. PubMed ID: 16886628
[TBL] [Abstract][Full Text] [Related]
35. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model.
Kang HJ; Lee SH; Price JE; Kim LS
Breast J; 2009; 15(3):223-9. PubMed ID: 19645775
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones.
Engel JB; Schally AV; Dietl J; Rieger L; Hönig A
Mol Pharm; 2007; 4(5):652-8. PubMed ID: 17705441
[TBL] [Abstract][Full Text] [Related]
37. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
[TBL] [Abstract][Full Text] [Related]
38. Combination effects of SC144 and cytotoxic anticancer agents.
Oshima T; Cao X; Grande F; Yamada R; Garofalo A; Louie S; Neamati N
Anticancer Drugs; 2009 Jun; 20(5):312-20. PubMed ID: 19322070
[TBL] [Abstract][Full Text] [Related]
39. A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.
Kogan NM; Schlesinger M; Peters M; Marincheva G; Beeri R; Mechoulam R
J Pharmacol Exp Ther; 2007 Aug; 322(2):646-53. PubMed ID: 17478614
[TBL] [Abstract][Full Text] [Related]
40. Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
J Urol; 2004 Feb; 171(2 Pt 1):911-5. PubMed ID: 14713852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
